Medical technology company HeartBeam Inc (NASDAQ: BEAT) announced on Monday that it has received FDA 510(k) clearance for its groundbreaking at-home heart monitoring system. The HeartBeam device is the first cable-free, portable ECG system capable of capturing high-fidelity heart signals from three directions, enabling advanced arrhythmia diagnostics and comprehensive cardiac assessments outside of medical facilities.

The credit card-sized device allows patients to record a 30-second ECG anytime they experience symptoms. Guided by a mobile app, the system transmits the data to the cloud, where it is processed and reviewed by physicians alongside the patient's medical history. This approach aims to reduce delays in cardiac care and provide actionable insights.

HeartBeam plans to launch an Early Access Program to gather feedback from patients and physicians, paving the way for commercial rollout. The FDA clearance establishes a foundation for future advancements, including the introduction of synthesized 12-lead ECG capabilities, AI-based arrhythmia detection algorithms and heart attack risk scoring.

Recent studies highlight the device's potential, with its technology demonstrating accuracy comparable to standard 12-lead ECGs for detecting coronary occlusions and improving arrhythmia detection through AI algorithms. HeartBeam aims to leverage its patented technology to offer longitudinal cardiac health insights, potentially predicting conditions before symptoms emerge.

Based in the US, HeartBeam holds 17 patents for its technology and seeks to redefine cardiac care by empowering patients and physicians with easy access to high-quality cardiac intelligence, potentially transforming care for millions worldwide.